Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Thrombosis Research Institute
London, England, United Kingdomtri-london.ac.uk ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The institute has pioneered the use of heparin for thrombosis prevention and was instrumental in developing low molecular weight heparins. It continues to lead large-scale clinical studies on antithrombotic therapies and registries for cardiovascular outcomes. Its work has contributed significantly to global guidelines for the management of blood clots. No proprietary drugs or commercial products are developed by TRI itself.
- Therapeutic areas
- CardiovascularHematology
- Modalities
- Small moleculeBiologicDeviceNon-pharmacological therapy
- Industry
- Academic Hospital/University/Research
02
Partnerships
Academic Health Science PartnershipUCL PartnersInternational network of over 2,500 research centers across ~40 countries
Beyond the preview
Go deeper on Thrombosis Research Institute.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Thrombosis Research Institute.